The adjunctive of effect of telmisartan in patients with hypertension uncotrolled on current antihypertensive therapy

International Journal of Clinical Practice

Volumn 57, Issue 10, 2003, Pages 861-866

  Gil Extremera, Blas ^a   Ma, P T S ^b   Yulde, J ^c   Kalnins, U ^d   Harkin, N ^e   Williams, L ^e  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b Heart Health Institute   (Canada)

^c Philippine Heart Centre   (Philippines)

^d PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; PLACEBO; TELMISARTAN; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; DRUG TOLERABILITY; EAR NOSE THROAT DISEASE; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SYSTOLIC BLOOD PRESSURE; VIRUS INFECTION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0347765700     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.
2. Moser M, Black HR. The role of combination therapy in the treatment of hypertension. Am J Hypertens 1998; 11: 73S-78S.
3. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
4. Messerli FH. Combination therapy in hypertension. J Hum Hypertens 1992; 6(suppl 2): S19-S21.
5. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 1967; 202: 1028-1034.
6. White WB. Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit 2001; 6: 63-72.
7. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334: 1649-1654.
8. Lacourcière Y, Lenis J, Orchard R et al. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monit 1998; 3: 295-302.
9. Neutel JM, Smith DHG. Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998; 15: 206-217.
10. Smith DHG, Neutel JM, Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther 1998; 15: 229-240.
11. Neutel JM, Frishman WH, Oparil S et al. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther 1999; 6: 161-166.
12. Mallion JM, Siché JP, Lacourcière Y et al. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13: 657-664.
13. Karlberg BE, Lins L-E, Hermansson K et al. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J Hypertens 1999; 17: 293-302.
14. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001; 61: 1501-1529.
15. Neutel JM, Klein C, Meinicke TW et al. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. Blood Press 2002; 11: 302-309.
16. Freytag F, Holwerda NJ, Karlberg BE et al. Long-term exposure to telmisartan as monotherapy or combination therapy: efficacy and safety. Blood Press 2002; 11: 173-181.
17. McGill JB, Reilly PA. Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clin Cardiol 2001; 24: 66-72.
18. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001; 23: 833-850.
19. Lacourcière Y, Tytus R, O'Keefe D et al. Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. J Hum Hypertens 2001; 15: 763-770.
20. Lacourcière Y. A new fixed-dose combination for added blood pressure control: telmisartan plus hydrochlorothiazide. J Int Med Res 2002; 30: 366-379.
21. Lacourcière Y, Martin K, on behalf of the Telmisartan Study Group. Comparison of a fixed-dose combination of telmisartan 40 mg plus hydrochlorothiazide 12.5 mg with telmisartan 40 mg in the control of mild-to-moderate hypertension. Am J Ther 2002; 9: 111-117.
22. Mancia G, Omboni S, Parati G. Assessment of antihypertensive treatment by ambulatory blood pressure. J Hypertens Suppl 1997; 15: S43-S50.
23. Mancia G, Bertinieri G, Grassi G et al. Effects of blood-pressure measurement by the doctor on patient's blood pressure and heart rate. Lancet 1983; ii: 695-698.
24. Benz JR, Black HR, Graff A et al. Valsartan and hydrochlorothiazide in patients with essential hypertension: a multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12: 861-866.
25. Benedict CR. Safe and effective management of hypertension with fixed-dose combination therapy: focus on losartan plus hydrochlorothiazide. Int J Clin Pract 2000; 54: 48-54.
26. MacKay JH, Arcuri KE, Goldberg AI et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension: a double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996; 156: 278-285.
27. Kochar M, Guthrie R, Triscari J et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12: 797-805.
28. Melian EB, Jarvis B. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension. Drugs 2002; 62: 787-816.
29. Burt VL, Cutler JA, Higgins M et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the Health Examination Surveys, 1960-1991. Hypertension 1995; 26: 60-69.
30. Mancia G, Sega R, Milesi C et al. Blood-pressure control in the hypertensive population. Lancet 1997; 349: 454-457.
31. Weir MR. The rationale for combination versus single-entity therapy in hypertension. Am J Hypertens 1998; 11(suppl 10): 163S-169S.
32. Neutel JM. Low-dose antihypertensive combination therapy: its rationale and role in cardiovascular risk management. Am J Hypertens 1999; 12(8 Pt 2): 73S-79S.
33. Edoute Y, Nagachandran P, Svirski B et al. Cardiovascular adverse drug reaction associated with combined beta-adrenergic and calcium entry-blocking agents. J Cardiovasc Pharmacol 2000; 35: 556-559.
34. Hansson L. 'Why don't you do as I tell you?' Compliance and antihypertensive regimens. Int J Clin Pract 2002; 56: 191-196.
35. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-645.
36. Eisen SA, Miller DK, Woodward RS et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881-1884.